Octreotide LA is under clinical development by Camurus and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Octreotide LA’s likelihood of approval (LoA) and phase transition for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) took place on 09 Sep 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Octreotide LA Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Octreotide LA overview

Octreotide long-acting (CAM-2029) is under development for the treatment of coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome, gastroenteropancreatic neuroendocrine tumor, polycystic kidney disease, polycystic liver disease, acromegaly and neuroendocrine tumors with carcinoid symptoms. It is administered through subcutaneous route. It acts by targeting somatostatin receptor. The drug candidate is a next-generation octreotide depot and it is developed based on FluidCrystal injectable depot technology.

Camurus overview

Camurus, a subsidiary of Sandberg Development AB, is a pharmaceutical company. It carries out development and commercialization of treatments for the patients suffering from chronic diseases. The company’s major products include CAM2038 to treat chronic pain; CAM2029 to treat acromegaly, GEP-NET and PLD; CAM4072 to treat genetic obesity disorders; CAM2032 to treat Prostate cancer; CAM2043 to treat pulmonary arterial hypertension and raynaud’s phenomenon; CAM4071 to treat endocrine disorders; buvidal drug candidates. It sells drugs under the brand name of Episil, FluidCrystal. The company has developmental and commercial collaborations with biotechnology and pharmaceutical companies for product development. Camurus is headquartered in Lund, Sweden.

Quick View Octreotide LA LOA Data

Report Segments
  • Innovator
Drug Name
  • Octreotide LA
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Gastrointestinal
  • Genetic Disorders
  • Hormonal Disorders
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.